¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"antibody dependent cellular cytotoxicity"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • cellular migration
    ¼¼Æ÷À̵¿
  • cellular nevus
    ¼¼Æ÷Ãæ½Ç¸ð¹Ý
  • cellular oncogene
    ¼¼Æ÷Á¾¾çÀ¯ÀüÀÚ
  • cellular protooncogene
    ¼¼Æ÷DzÁ¾¾çÀ¯ÀüÀÚ
  • cellular radiobiology
    ¼¼Æ÷¹æ»ç¼±»ý¹°ÇÐ
  • cellular sensitivity
    ¼¼Æ÷¹Î°¨µµ
  • mixed cellular cast
    È¥ÇÕ¼¼Æ÷¿øÁÖ
  • anchorage dependent growth
    ºÎÂøÁõ½Ä, ºÎÂø¹ßÀ°
  • bradycardia dependent bundle branch block
    ´À¸°¸Æ¹ÚÀÇÁ¸´Ù¹ß°¥·¡Â÷´Ü, ¼­¸ÆÀÇÁ¸¼º°¢Â÷´Ü
  • density dependent inhibition
    ¹ÐµµÀÇÁ¸¾ïÁ¦
  • dependent
    1. ÀÇÁ¸- 2. ÀÇÁ¸¼º 3. Á¾¼ÓÀû
  • dependent drainage
    üÀ§¹è¾×(¹ý)
  • dependent edema
    üÀ§ÀÇÁ¸ºÎÁ¾
  • dependent personality disorder
    ÀÇÁ¸ÀΰÝÀå¾Ö
  • dependent variable
    Á¾¼Óº¯¼ö
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • polyclonal antibody
    ´ÙŬ·ÐÇ×ü
  • antigen-antibody reaction
    Ç׿øÇ×ü¹ÝÀÀ
  • antibody synthesis
    Ç×üÇÕ¼º
  • antibody titer
    Ç×ü°¡
  • antibody screening test
    Ç×ü¼±º°°Ë»ç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • cellular invagination
    ¼¼Æ÷ÇÔÀÔ
  • cellular ischemia
    ±¹¼ÒÇãÇ÷
  • cellular migration
    ¼¼Æ÷À̵¿
  • cellular nevus
    ¼¼Æ÷¸ð¹Ý
  • cellular oncogene
    ¼¼Æ÷Á¾¾çÀ¯ÀüÀÚ
  • cellular protooncogene
    ¼¼Æ÷¿ø¹ß¾ÏÀ¯ÀüÀÚ
  • cellular radiobiology
    ¼¼Æ÷¹æ»ç¼±»ý¹°ÇÐ
  • cellular sensitivity
    ¼¼Æ÷¹Î°¨µµ
  • cellular type
    ¼¼Æ÷Çü
  • mixed cellular cast
    È¥ÇÕ¼¼Æ÷¿øÁÖ
  • impaired cellular immunity
    ¼¼Æ÷¸é¿ªºÎÀü
  • anchorage dependent growth
    ºÎÂøÁõ½Ä, ºÎÂø¹ßÀ°
  • thymus-dependent antigen
    °¡½¿»ùÀÇÁ¸Ç׿ø
  • thymus-dependent area
    °¡½¿»ùÀÇÁ¸±¸¿ª
  • bradycardia dependent bundle branch block
    ´À¸°¸Æ¹ÚÀÇÁ¸°¢Â÷´Ü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • antigen, thymus-dependent
    Èä¼±ÀÇÁ¸Ç׿ø, °¡½¿»ùÀÇÁ¸Ç׿ø
  • area, thymus-dependent
    Èä¼±ÀÇÁ¸¿ª, °¡½¿»ùÀÇÁ¸¿ª
  • frequency dependent
    Á֯ļö ÀÇÁ¸Çü
  • hypnotic-dependent disorder
    ¼ö¸éÁ¦ÀÇÁ¸Àå¾Ö, ~º´
  • personality disorder, dependent
    ÀÇÁ¸¼º(ëîðíàõ) ÀΰÝÀå¾Ö
  • rate dependent bundle branch block
    ½É¹Ú¼öÀÇÁ¸¼º °¢Â÷´Ü.
  • DF3 antibody
    DF3 Ç×ü
  • DL antobody => Donath-Landsteiner antibody
    DL Ç×ü
  • Donath-Landsteiner antibody
    µµ³ª¾²¶õÆ®½ºÅ¸ÀÌ³Ê Ç×ü
  • FTA (fluorescent treponemal antibody)
    ¸Åµ¶Çü±¤Ç×ü °Ë»ç¹ý
  • Fy antigen/antibody
    Fy Ç׿ø/Ç×ü
  • Gp 120/160 antibody
    Gp 120/160 Ç×ü
  • Gp 24 antibody
    Gp 24 Ç×ü
  • I antibody
    I Ç×ü
  • Jk antigen/antibody
    JkÇ׿ø/Ç×ü
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • bradycardia dependent bundle branch block
    ¼­¸ÆÀÇÁ¸¼º °¢Â÷´Ü(ßïØæëîðíàõ ÊÅó´Ó¨).
  • bradycardia dependent bundle branch block
    ¼­¸ÆÀÇÁ¸¼º °¢Â÷´Ü.
  • cell, thymus-dependent
    °¡½¿»ùÀÇÁ¸¼¼Æ÷, Èä¼±ÀÇÁ¸¼¼Æ÷
  • cyclic AMP-dependent kinase
    °í¸® AMP ÀÇÁ¸¼º Ű³ªÁ¦
  • density dependent inhibition
    ¹ÐµµÀÇÁ¸ ÀúÇØ.
  • dependent
    °¡¶ó¾ÉÀº, ¾Æ·¡ÂÊÀÇ, ÀÇÁ¸ÀûÀÎ
  • dependent personality disorder
    ÀÇÁ¸¼º ÀΰÝÀå¾Ö(ëîðíàõ ìÑÌ«î¡äô)
  • dependent strain
    ÀÇÁ¸ÁÖ(Ëô̡̡).
  • dependent variable
    Á¾¼Óº¯¼ö(ÊÙËÒËà).
  • diabetes mellitus,insulin-dependent
    Àν¶¸° ÀÇÁ¸¼º(¡­ëîðíàõ)
  • diabetes mellitus,non-insulin-dependent
    ºñ-Àν¶¸° ÀÇÁ¸¼º(Þª¡­)
  • edema,dependent
    üÀ§¼º(ô÷êÈàõ)
  • frequency dependent
    Á֯ļö ÀÇÁ¸Çü
  • frequency-dependent
    Á֯ļö ÀÇÁ¸Çü (ñ²÷î⦠ëîðíû¡)
  • hormone dependent
    È£¸£¸óÀÇÁ¸¼º.
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • anti-idiotype antibody
    Ç×(ù÷)À̵ð¿ÀŸÀÌÇÁ Ç×ü(ù÷ô÷)
  • anti-immunoglobulin antibody
    Ç׸鿪(ù÷Øóæ¹)±Û·ÎºÒ¸° Ç×ü(ù÷ô÷)
  • antibody
    Ç×ü(ù÷ô÷)
  • antibody binding fraction
    Ç×ü°áÇÕºÐȹ (ù÷ô÷Ì¿ùêÝÂüò)
  • antibody combining site
    Ç×ü°áÂø(ù÷ô÷Ì¿ó·)ÀÚ¸®
  • antibody diversity
    Ç×ü ´Ù¾ç¼º(ù÷ô÷ÒýåÆàõ)
  • antibody fixation
    Ç×ü °íÁ¤(ù÷ô÷ͳïÒ)
  • antibody formation
    Ç×ü Çü¼º(ù÷ô÷û¡à÷)
  • antibody heterogeneity
    Ç×ü ºÒ±ÕÀϼº(ù÷ô÷ÝÕгìéàõ)
  • antibody mediated hypersensitivity
    Ç×ü ¸Å°³ °ú¹ÎÁõ(ù÷ô÷ØÚ˿ΦÚÂñø)
  • antibody response
    Ç×ü ´ëÀÀ(ù÷ô÷Óßëë)
  • antibody specificity
    Ç×ü ƯÀ̼º(ù÷ô÷÷åì¶àõ)
  • antibody titer
    Ç×ü¿ª°¡(ù÷ô÷æ³Ê¤)
  • antibody valence
    Ç×ü°¡(ù÷ô÷ʤ)
  • antibody-excess zone
    Ç×ü°úÀ×±¸¿ª(ù÷ô÷Φí¥Ï¡æ´)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
ACA abnormal coronary artery; acrodermatitis chronica atrophicans; acute cerebellar ataxia; adenocarcino...
CDC calculated date of confinement; cancer diagnosis center; capillary diffusion capacity; cell division...
AMC academic medical center; acetylmethyl carbinol; Animal Medical Center; antibody-mediated cytotoxicit...
AMA against medical advice; alkaline membrane assay; American Management Association; American Medical A...
NA Avogadro constant or number; nalidixic acid; Narcotics Anonymous; network administrator; neuraminida...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
CAMC Complement-dependent antibody-mediated cytotoxicity
ADCC Antibody dependent cellular cytotoxic
MICC Mitogen induced cellular cytotoxicity
CDC Complement dependent cytotoxicity
LDCC Lectin dependent cell mediated cytotoxicity
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • thymus-dependent cell
    Èä¼± ÀÇÁ¸ ¼¼Æ÷
  • acute cellular rejecion
    ±Þ¼º ¼¼Æ÷¼º °ÅºÎ
    ÀϹÝÀûÀ¸·Î ÀÌ½Ä ÈÄ ¼ö °³¿ù ³»¿¡ ¹ß»ýÇϸç Ç÷û Å©·¹¾ÆÆ¼´ÑÄ¡°¡ »ó½ÂÇÏ°í ±Þ¼º ½ÅºÎÀüÀÇ ÀÓ»óÁõ»óÀ» µ¿¹ÝÇÑ´Ù. Á¶Á÷ÇÐÀûÀ¸·Î´Â °£Áú³» ´ÜÇÙ¼¼Æ÷ ħÀ±ÀÌ ¸Å¿ì °­ÇÏ°Ô ³ªÅ¸³ª¸ç, ºÎÁ¾ ¹× °æµµÀÇ °£Áú³» ÃâÇ÷À» º¸À̴µ¥ »ç¶÷ÀÇ °æ¿ì ´ÜÇÙ¼¼Æ÷´Â ÁÖ·Î Áß°£ Å©±â¿Í ÀÛÀº ¸²ÇÁ±¸·Î ±¸¼ºµÇ¾î ÀÖ°í dzºÎÇÑ È£¿°±â¼º ¼¼Æ÷Áú°ú ¼öÆ÷¼º ÇÙÀ» °¡Áø ¼Ò¼öÀÇ ÇüÁú¼¼Æ÷ ħÀ±µµ º¼ ¼ö ÀÖ´Ù.
  • cellular
    ¼¼Æ÷¼º, ¼¼Æ÷ÀÇ
  • cellular adhesiveness
    ¼¼Æ÷ ºÎÂø¼º
    ¼¼Æ÷°£¿¡ ¹°¸®ÀûÀÎ Àη ¶Ç´Â Á¢Ã˹°Ã¼ÀÇ Ç¥¸é°£¿¡ Á¸ÀçÇÏ´Â ºÐÀÚÀη¿¡ ÀÇÇÑ ºÎÂø¼º.
  • cellular axis
    ¼¼Æ÷ Ãà
    ¼¼Æ÷¿¡¼­ ¾î¶² ±¸Á¶¹°À̳ª ȸÀüü°¡ ÁÖÀ§¸¦ µ¹°í ÀÖ´Â Á÷¼±.
  • cellular blue nevus
    ¼¼Æ÷¼º û»ö ¸ð¹Ý
    û»ö ¸ð¹ÝÀÇ Æ¯ÀÌÇÑ º¯ÇüÀ¸·Î¼­ ÀÓ»óÀû ¹× Á¶Á÷ÇÐÀûÀ¸·Î ¾Ç¼º Èæ»öÁ¾À¸·Î ¿ÀÀεDZ⠽±´Ù. À̰ÍÀº µÐºÎ¿Í õ¹Ì°ñ ºÎÀ§¿¡ È£¹ßÇϸç Ä¿´Ù¶õ û»ö ¶Ç´Â Èæ»öÀÇ ´Ü´ÜÇÑ °áÀý·Î ³ªÅ¸³­´Ù.
  • cellular cementum
    ¼¼Æ÷¼º ¹é¾ÇÁú
    Ä¡¾ÆÀÇ Ä¡±Ù¸éÀ» µ¤°í ÀÖ´Â ¼®È¸È­µÈ ¹°ÁúÀÇ ºÎºÐ. °ñ°ú ºñ½ÁÇÏ¸ç ¹é¾Ç ¼¼Æ÷°¡ ¼Ò¿Í³»¿¡¼­ ¹¯Çô ÀÖ´Ù. ¶ÇÇÑ, ¹é¾ÇÁúÀÇ ¼¼°üÀ» µû¶ó ¿øÇüÁú µ¹±â°¡ »¸¾î ÀÖ°í ÀÌ´Â ÀÎÁ¢ÇÑ ¼Ò¿ÍÀÇ ¼¼°ü°ú ¹®ÇÕÇÑ´Ù. ¼Ò¿Í´Â ÃþÆÇÇüÀ¸·Î Á¤·ÄÇÏ¿© ¼®È¸Áú¿¡ »êÀçÇØ ÀÖ´Ù. ¼¼Æ÷¼º ¹é¾ÇÁúÀº ÁÖ·Î Ä¡±ÙÀÇ Ä¡±Ù´Ü ºÎºÐ¿¡ ±¹¼ÒÈ­µÇ¾î Àִµ¥ ¹«¼¼Æ÷¼º ¹é¾ÇÁú À§¿¡ Ä§ÂøµÉ ¼öµµ ÀÖ°í, ¹é¾ÇÁú Èí¼ö ºÎÀ§¿¡¼­ Ä¡À¯ ÀÛ¿ëÀ» ÇÏÁö ¸øÇÒ ¼öµµ ÀÖ´Ù.
  • cellular connective tissue
    ¼¼Æ÷¼º °áÇÕ Á¶Á÷
    ¼¼Æ÷·Î »çÀ̰¡ ¿¬°áµÇ¾î ÀÖ´Â Á¶Á÷.
  • cellular deficiency
    ¼¼Æ÷ °áÇÌ
    ¼¼Æ÷°¡ À¯ÀüÀû ȤÀº ÀÚ°¡¸é¿ªÀû ¿äÀÎÀ¸·Î ÀÎÇØ¼­ °áÇÌµÈ °Í.
  • cellular detection
    ¼¼Æ÷ °ËÃâ
    ¼¼Æ÷ÀÇ Á¸À縦 °ËÃâÇÏ´Â °Í.
  • cellular hypersensitivity
    ¼¼Æ÷¼º °ú¹Î¹ÝÀÀ
    ¼¼Æ÷¿¡ ´ëÇÏ¿© °úÀ×¹ÝÀÀÀ» ³ªÅ¸³»´Â ¹æÇâÀ¸·Î ¹ÝÀÀ¼ºÀÌ º¯È­ÇÑ »óÅÂ.
  • cellular infiltration
    ¼¼Æ÷ ħÀ±
    ¼¼Æ÷°¡ ħÀ±¿¡ ÀÇÇÏ¿© Ä§ÂøµÈ °Í.
  • cellular invagination
    ¼¼Æ÷ ÇÔÀÔ
    ¼¼Æ÷ÀÇ ¾î¶² ºÎºÐÀÌ ´Ù¸¥ ºÎºÐ³»¿¡ ÇÔÀÔÇÏ´Â °Í.
  • cellular layer
    ¼¼Æ÷ Ãþ
    ¼¼Æ÷°¡ °ÅÀÇ ÀÏÁ¤ÇÑ µÎ²²ÀÇ, ȬÀ̺Ҹð¾çÀÇ Á¶Á÷ ±¸Á¶¸¦ °¡Áö´Â °Í.
  • cellular membrane
    ¼¼Æ÷¼º ¸·
    ¼¼Æ÷ÀÇ Ç¥¸éÀ» µ¤°Å³ª °øµ¿ÀÇ ³»¸éÀ» µ¤´Â, ¶Ç´Â °ø°£À̳ª ±â°üÀ» ³ª´©´Â ¾ãÀº ÃþÀÇ Á¶Á÷.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
cellular immunity deficiency syndrome <syndrome> A syndrome marked by increased susceptibility to infection, especially to viral infection, associated with defective functioning of the mechanism responsible for acquired immunity of the cell-mediated kind.
See: immunodeficiency.
(05 Mar 2000)
cellular immunodeficiency with abnormal immunoglobulin synthesis An ill-defined group of sporadic disorders of unknown cause, occurring in both males and females and associated with recurrent bacterial, fungal, protozoal, and viral infections; there is thymic hypoplasia with depressed cellular (T-lymphocyte) immunity combined with defective humoral (B-lymphocyte) immunity, although immunoglobulin levels may be normal.
Synonym: Nezelof syndrome, Nezelof type of thymic alymphoplasia.
(05 Mar 2000)
cellular infiltration Migration of cells from their sources of origin, or direct extension of cells as a result of unusual growth and multiplication, thereby resulting in fairly well-defined foci, irregular accumulations, or diffusely distributed individual cells in the connective tissue and interstices of various organs and tissues; used especially with reference to such changes associated with inflammations and certain types of malignant neoplasms.
(05 Mar 2000)
cellular microbiology <study> A new discipline emerging at the interface between cell biology and microbiology. One major focus of this new field is on the interference of pathogenic bacteria with many eukaryotic cell functions, such as maturation of intracellular compartments, internal cellular communication, or even cell division and differentiation.
The study of cellular mcirobiology in this respect, is providing a sophisticaled tool kit for mammalian cell biologists.
(26 Mar 1998)
cellular mosaicism A chimerism in which a tissue contains cells from different zygotes; e.g., in humans, involving erythrocytes.
(05 Mar 2000)
cellular oncogene <molecular biology> A normal gene that, when mutated or improperly expressed, can cause cancer to develop.
(09 Oct 1997)
cellular pathology The interpretation of diseases in terms of cellular alterations, i.e., the ways in which cells fail to maintain homeostasis, sometimes used as a synonym for cytopathology.
(05 Mar 2000)
cellular polyp A polyp that consists of benign neoplastic tissue derived from glandular epithelium.
Synonym: cellular polyp, polypoid adenoma.
(05 Mar 2000)
cellular respiration <biochemistry> The conversion within the cell of nutrients (such as sugar molecules) into chemical energy in the form of ATP, by reacting the food with oxygen (O2) until the food has completely been degraded into carbon dioxide and H2O.
(09 Oct 1997)
cellular retinoic acid binding protein <protein> A cytoplasmic fatty acid binding protein that acts as an initial receptor for the putative morphogen, retinoic acid.
(18 Nov 1997)
cellular slime mould See: Acrasidae.
(18 Nov 1997)
cellular tumour A tumour composed mainly of closely packed cells.
(05 Mar 2000)
immunity, cellular Those manifestations of the immune response which are mediated by antigen-sensitised T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role.
(12 Dec 1998)
aid to families with dependent children Financial assistance provided by the government to indigent families with dependent children who meet certain requirements as defined by the social security act, title IV, in the u.s.
(12 Dec 1998)
androgen-dependent secretory protease <enzyme> Glycoprotein from dog prostate; hydrolyzes arginine and lysine-containing amide and ester protease substrates
Registry number: EC 3.4.99.-
Synonym: ads-protease
(26 Jun 1999)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á